Sign In
9 Mar 2022 07:00
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
9 March 2022
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or "the Company")
Director Dealing
Alderley Park, 9 March 2022 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces the following dealing in the Company's ordinary shares of 1 pence each ("Ordinary Shares").
On 8 March 2022, 100,000 Ordinary Shares at a price of 22.25 pence each were purchased by Iain Ross, Chairman of the Company, through his self-invested personal pension (SIPP).
Following this purchase, Mr Ross is benefically interested in 400,000 Ordinary Shares representing 0.61 per cent of the Company's total issued share capital.
-Ends-
For more information, please contact:
| ||||||||||||||||||||||
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.
The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.
BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Iain Ross
| ||||
2. | Reason for the Notification | |||||
a) | Position/status | Non-Executive Chairman | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | BiVictriX Therapeutics plc | ||||
b) | LEI | 213800ZI85IZNA6N3L53 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 1 pence each GB00BNXH3K91 | ||||
Identification code | ||||||
b) | Nature of the transaction | Purchase of Ordinary Shares via SIPP | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: - Aggregated volume - Price |
| ||||
e) | Date of the transaction | 8 March 2022 | ||||
f) | Place of the transaction | AIM, London Stock Exchange | ||||
Follow the stocks
